Comparative Pharmacology
Head-to-head clinical analysis: CREON versus VIOKACE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CREON versus VIOKACE.
CREON vs VIOKACE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pancreatic enzyme replacement therapy; lipase, amylase, and protease hydrolyze fats, proteins, and starches respectively, compensating for exocrine pancreatic insufficiency.
Pancrelipase is a pancreatic enzyme replacement therapy that provides lipase, amylase, and protease to hydrolyze fats, starches, and proteins into absorbable forms in the small intestine, compensating for exocrine pancreatic insufficiency.
500 to 4,000 lipase units per gram of fat intake per meal, orally, with meals; typical adult dose: 25,000 to 75,000 lipase units per meal, up to 150,000 units/day. Capsules should be swallowed whole with water or juice; do not crush or chew.
500 lipase units/kg per meal orally, with snacks at half the meal dose. Maximum 2500 lipase units/kg per meal or 10,000 lipase units/kg per day.
None Documented
None Documented
Not applicable, as pancreatic enzymes act locally in the GI tract and are not systemically absorbed. The enzymes are inactivated by gastric acid and pepsin, resulting in an effective half-life of 30–45 minutes in the duodenum.
2-3 hours (enzymatic degradation in GI tract; clinical relevance: frequent dosing for exocrine pancreatic insufficiency)
Pancrelipase undergoes proteolytic digestion in the gastrointestinal tract; the enzymes are not absorbed systemically. Any residual activity is eliminated in feces. Renal excretion is negligible.
Primarily fecal via degradation in GI tract; minimal renal excretion (<2% unchanged)
Category C
Category C
Pancreatic Enzyme
Pancreatic Enzyme